Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RINGQUEST
2026-526048-10-00Phase 2Authorised
- Sponsor
- GUARD Consortium
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab tirumotecan in papillary renal cell carcinoma (PRCC), urothelial carcinoma (UC), bladder cancer and 1 more (2 cohorts), sponsored by GUARD Consortium. Primary endpoint: Objective response rate. Planned start Sep 2026; status: authorised.
02
Drugs
sacituzumab tirumotecan
03
Conditions
papillary renal cell carcinoma (PRCC)urothelial carcinoma (UC)bladder cancerbladder adenocarcinoma
Beyond the preview
Go deeper on 2026-526048-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526048-10-00.